Cartana secures $1M for a tech platform understanding the brain and its diseases.
Cartana, a Stockholm, Sweden-based company working on a digital platform for brain cell analysis, announced in a press release securing SEK 9.6M ($1M) in capital investment.
The money was provided by a group of Swedish investors via Sciety and includes a SEK 3M contribution from Almi Invest. The funding will be used for further development of the product and market launch.
Cartana, founded in 2017 and led by CEO Malte Kühnemund, developed NeuroKit, an optimized reagent kit that enables the mapping of hundreds of genes and cell types via In Situ Sequencing (ISS) in a single tissue section with high throughput and high sensitivity. The solution enables simultaneous analysis of hundreds of genes within all cells comprising a tissue, without losing tissue morphology, with high sensitivity and throughput.